Back to results
US 7,923,018 B2Granted
Vaccine
AssigneeIsis Innovation Limited
InventorsJoyce Susan Plested, Michael Paul Jennings, Margaret Anne Jaqueline Gidney, Andrew David Cox, James Clare Richards, Richard Edward Moxon
Life of this patent
Estimating the term…
Abstract
The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.
Claims2
An isolated lipopolysaccharide inner core of galE mutant of a strain Neisseria meningitidis immunotype L4 having the formula:
- wherein the isolated lipopolysaccharide inner core comprises an epitope of a Neisseria meningitidis immunotype L4, but not of Neisseria meningitidis immunotypes L1, L3, L7, L9, L10, L11 and L12, wherein said epitope has the phosphoethanolamine (PEtn) group linked to the position 6 of the HepII moiety of the lipopolysaccharide inner core, and wherein said epitope is specifically recognized by the monoclonal antibody A4 produced by the hybridoma deposited with the accession number IDAC 260900-2.
Dependencies are inferred from the claim text.